- Home
- FNGR vs TNGX Comparison
FNGR vs TNGX Comparison
Compare FNGR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- TNGX
- Stock Information
- Founded
- FNGR 2016
- TNGX 2014
- Country
- FNGR Singapore
- TNGX United States
- Employees
- FNGR N/A
- TNGX N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- TNGX Health Care
- Exchange
- FNGR Nasdaq
- TNGX Nasdaq
- Market Cap
- FNGR 259.4M
- TNGX 248.2M
- IPO Year
- FNGR N/A
- TNGX N/A
- Fundamental
- Price
- FNGR $3.02
- TNGX $2.22
- Analyst Decision
- FNGR
- TNGX Strong Buy
- Analyst Count
- FNGR 0
- TNGX 6
- Target Price
- FNGR N/A
- TNGX $12.20
- AVG Volume (30 Days)
- FNGR 1.3M
- TNGX 3.5M
- Earning Date
- FNGR 05-29-2025
- TNGX 05-12-2025
- Dividend Yield
- FNGR N/A
- TNGX N/A
- EPS Growth
- FNGR N/A
- TNGX N/A
- EPS
- FNGR N/A
- TNGX N/A
- Revenue
- FNGR $35,607,614.00
- TNGX $40,990,000.00
- Revenue This Year
- FNGR N/A
- TNGX N/A
- Revenue Next Year
- FNGR N/A
- TNGX N/A
- P/E Ratio
- FNGR N/A
- TNGX N/A
- Revenue Growth
- FNGR N/A
- TNGX 10.09
- 52 Week Low
- FNGR $1.03
- TNGX $1.03
- 52 Week High
- FNGR $5.20
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- FNGR 46.50
- TNGX 62.75
- Support Level
- FNGR $2.50
- TNGX $1.93
- Resistance Level
- FNGR $4.38
- TNGX $2.67
- Average True Range (ATR)
- FNGR 0.57
- TNGX 0.40
- MACD
- FNGR -0.18
- TNGX 0.07
- Stochastic Oscillator
- FNGR 19.26
- TNGX 59.59
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.